Compare Crowdstrike Holdings Inc (CRWD) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crowdstrike Holdings Inc vs Sanofi SA — how do they compare? Crowdstrike Holdings Inc trades at $275.04 (market cap $269.31B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Crowdstrike Holdings Inc is far larger — about 2.8× Sanofi SA's market cap, and Sanofi SA pays a 6.01% dividend while Crowdstrike Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crowdstrike Holdings Inc for 97 Days and Sanofi SA for 94 Days on average.
| CRWD | SNY | |
|---|---|---|
Market Cap | $269.31B | $95.18B |
Volume | 9,381,560 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $278.86 | $52.34 |
52-Week Low | $87.56 | $39.51 |
Typical Hold Time | 97 Days | 94 Days |
Enterprise Value | $265.11B | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CrowdStrike (CRWD) trades at $275.04, up 3.62% today and near its all-time high, with a bullish technical signal from moving averages. The company shows strong revenue growth, reaching $3.95B in 2025, though net income remains negative at -$19.27M. Recent earnings beats and positive analyst sentiment (76% buy ratings) highlight momentum, while the stock trades at elevated valuation multiples like P/S of 49.86. Key developments include expansion into the OpenAI Marketplace and AI-driven cybersecurity demand.
Outlook: CrowdStrike's growth trajectory and AI positioning offer upside, but high valuations and profitability challenges pose risks. Analyst consensus target is $235.74, below current price, suggesting caution despite bullish sentiment. Competitive pressures and execution on net income conversion are critical for sustained gains.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
